Physician profile
John H Dang
NPI 1366612509
$3,252.71
in general payments reported to CMS, 2019-2025
11 companies · $576 in 2025
The $576 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,191 · 2020: $27.64 · 2021: $532 · 2022: $320 · 2023: $298 · 2024: $309 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883 · Entertainment: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $882.86 |
| Entertainment | $299.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $643.72 | 2019-2024 | Myday Contact Lens, Biofinity Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $642.32 | 2019-2021 | |
| Alcon Vision LLC | $547.35 | 2021-2025 | Precision 1 |
| Optos, INC. | $455.06 | 2019-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Bausch & Lomb Americas INC. | $263.11 | 2022-2025 | Infuse |
| Lkc Technologies, INC. | $242.11 | 2024-2025 | |
| Astellas Pharma US INC | $121.86 | 2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $115.66 | 2019 | |
| Shire North American Group INC | $102.44 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $97.66 | 2024 | |
| Glaukos Corporation | $21.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.